PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Biofrontera Inc. (BFRI)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS09077D1000
CUSIP09077D100
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$7.84M
EPS-$13.02
Revenue (TTM)$34.07M
Gross Profit (TTM)$13.49M
EBITDA (TTM)-$20.85M
Year Range$0.61 - $13.48
Target Price$16.00
Short %1.80%
Short Ratio0.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Biofrontera Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Biofrontera Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-63.58%
17.14%
BFRI (Biofrontera Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Biofrontera Inc. had a return of -39.71% year-to-date (YTD) and -86.31% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-39.71%5.06%
1 month41.53%-3.23%
6 months-63.54%17.14%
1 year-86.31%20.62%
5 years (annualized)N/A11.54%
10 years (annualized)N/A10.37%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-51.99%-36.99%83.77%
20231.27%-46.41%-28.81%-17.21%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BFRI is 12, indicating that it is in the bottom 12% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of BFRI is 1212
Biofrontera Inc.(BFRI)
The Sharpe Ratio Rank of BFRI is 2020Sharpe Ratio Rank
The Sortino Ratio Rank of BFRI is 1313Sortino Ratio Rank
The Omega Ratio Rank of BFRI is 1414Omega Ratio Rank
The Calmar Ratio Rank of BFRI is 55Calmar Ratio Rank
The Martin Ratio Rank of BFRI is 1010Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biofrontera Inc. (BFRI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BFRI
Sharpe ratio
The chart of Sharpe ratio for BFRI, currently valued at -0.62, compared to the broader market-2.00-1.000.001.002.003.00-0.62
Sortino ratio
The chart of Sortino ratio for BFRI, currently valued at -1.20, compared to the broader market-4.00-2.000.002.004.00-1.20
Omega ratio
The chart of Omega ratio for BFRI, currently valued at 0.86, compared to the broader market0.501.001.500.86
Calmar ratio
The chart of Calmar ratio for BFRI, currently valued at -0.87, compared to the broader market0.001.002.003.004.005.00-0.87
Martin ratio
The chart of Martin ratio for BFRI, currently valued at -1.42, compared to the broader market0.0010.0020.0030.00-1.42
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.76, compared to the broader market-2.00-1.000.001.002.003.001.76
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.57, compared to the broader market-4.00-2.000.002.004.002.57
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.001.002.003.004.005.001.33
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.04, compared to the broader market0.0010.0020.0030.007.04

Sharpe Ratio

The current Biofrontera Inc. Sharpe ratio is -0.62. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.62
1.76
BFRI (Biofrontera Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Biofrontera Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.37%
-4.63%
BFRI (Biofrontera Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Biofrontera Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biofrontera Inc. was 99.74%, occurring on Feb 14, 2024. The portfolio has not yet recovered.

The current Biofrontera Inc. drawdown is 99.37%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.74%Dec 27, 2021537Feb 14, 2024
-46.2%Nov 29, 20216Dec 6, 202111Dec 21, 202117
-43.99%Nov 1, 202116Nov 22, 20212Nov 24, 202118
-4.81%Dec 22, 20211Dec 22, 20211Dec 23, 20212

Volatility

Volatility Chart

The current Biofrontera Inc. volatility is 55.80%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2024FebruaryMarchApril
55.80%
3.27%
BFRI (Biofrontera Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biofrontera Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items